In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...

In this piece, we provide selected highlights from the 63rd American Society of Hematology annual meeting, held from December 11-14th 2021.

Some of the best links we picked up around the internet

This week’s CRISPR trial update brings you the latest developments from ongoing CRISPR clinical trials, including expansion of Intellia Therapeutics’...

The FDA recently placed a temporary hold on a clinical trial with TALEN gene-edited CAR T-cells. A patient enrolled in this trial developed...

This week’s clinical update focuses on a newly posted Phase 1 clinical trial for a CRISPR-edited CAR-T therapy for relapsed or refractory CD19+...

This week’s update looks at P-BCMA-ALLO1, a Cas-CLOVER-edited allogeneic CAR-T candidate that is being developed for the treatment of multiple...

Poseida Therapeutics' unique approach to gene editing and delivery addresses some of the major obstacles faced within cell and gene therapy...